PMID- 33085741
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 1745-7270 (Electronic)
IS  - 1672-9145 (Linking)
VI  - 52
IP  - 10
DP  - 2020 Oct 19
TI  - miR-150 regulates glucose utilization through targeting GLUT4 in 
      insulin-resistant cardiomyocytes.
PG  - 1111-1119
LID - 10.1093/abbs/gmaa094 [doi]
AB  - MicroRNAs (miRNAs) play an important role in cardiac function and metabolism. 
      However, whether they regulate insulin resistance (IR) of cardiomyocytes remains 
      unclear. The aim of the present study was to shed light on this issue with a 
      focus on miR-150. We found here that miR-150 level was elevated in myocardium of 
      type 2 diabetes mellitus (T2DM) rat model and in insulin-resistant cardiomyocytes 
      induced by high glucose (25 mM) and high insulin (1 muM). Deregulation of miR-150 
      downregulated the protein and mRNA levels of glucose transporter 4 (GLUT4) as 
      assessed by western blot, real-time polymerase chain reaction (qPCR), and 
      immunofluorescence assays. Overexpression of miR-150 inhibited glucose 
      utilization in cardiomyocytes as detected by 2-deoxyglucose transport and glucose 
      consumption assays. In contrast, knockdown of miR-150 significantly increased 
      glucose uptake in cardiomyocytes. Moreover, GLUT4 translocation was increased 
      after transfection of miR-150 inhibitor (AMO-150). Collectively, miR-150 reduced 
      glucose utilization by directly decreasing the expression and translocation of 
      GLUT4 in the cardiomyocytes with IR and therefore might be a new therapeutic 
      target for metabolic diseases such as T2DM.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the 
      Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological 
      Sciences, Chinese Academy of Sciences. All rights reserved. For permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Ju, Jin
AU  - Ju J
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
FAU - Xiao, Dan
AU  - Xiao D
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
AD  - Department of Psychiatry, Qiqihar Medical University, Qiqihar 161006, China.
FAU - Shen, Nannan
AU  - Shen N
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
AD  - Department of Pharmacy (Department of Clinical Medicine), ShaoXing Municipal 
      Hospital, Shaoxing 312000, China.
FAU - Zhou, Tong
AU  - Zhou T
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
AD  - Department of Pharmacy, the First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, China.
FAU - Che, Hui
AU  - Che H
AD  - Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
FAU - Li, Xia
AU  - Li X
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
FAU - Zhang, Shuqian
AU  - Zhang S
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
FAU - Mokembo, Justine Nyakango
AU  - Mokembo JN
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
FAU - Jha, Nabanit Kumar
AU  - Jha NK
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
FAU - Monayo, Seth Mikaye
AU  - Monayo SM
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
FAU - Wang, Zhiguo
AU  - Wang Z
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
FAU - Zhang, Yong
AU  - Zhang Y
AD  - Department of Pharmacology, Harbin Medical University (The State-Province Key 
      Laboratories of Biomedicine-Pharmaceutics of China), Harbin 150081, China.
AD  - Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Harbin 
      150086, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Acta Biochim Biophys Sin (Shanghai)
JT  - Acta biochimica et biophysica Sinica
JID - 101206716
RN  - 0 (Glucose Transporter Type 4)
RN  - 0 (Insulin)
RN  - 0 (MIRN150 microRNA, rat)
RN  - 0 (MicroRNAs)
RN  - 0 (Slc2a4 protein, rat)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Biological Transport/genetics
MH  - Diabetes Mellitus, Experimental/genetics/metabolism
MH  - Glucose/metabolism
MH  - Glucose Transporter Type 4/genetics/*metabolism
MH  - Heart/physiopathology
MH  - Insulin/metabolism
MH  - Insulin Resistance/*genetics
MH  - Male
MH  - MicroRNAs/antagonists & inhibitors/*genetics/*metabolism
MH  - Myocardium/cytology/metabolism
MH  - Myocytes, Cardiac/cytology/*metabolism/ultrastructure
MH  - Primary Cell Culture
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - GLUT4
OT  - insulin resistance
OT  - miR-150
OT  - type 2 diabetes mellitus
EDAT- 2020/10/22 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/10/21 15:36
PHST- 2020/02/26 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
PHST- 2020/10/21 15:36 [entrez]
AID - 5934597 [pii]
AID - 10.1093/abbs/gmaa094 [doi]
PST - ppublish
SO  - Acta Biochim Biophys Sin (Shanghai). 2020 Oct 19;52(10):1111-1119. doi: 
      10.1093/abbs/gmaa094.